Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.

Hopkins AC, Yarchoan M, Durham JN, Yusko EC, Rytlewski JA, Robins HS, Laheru DA, Le DT, Lutz ER, Jaffee EM.

JCI Insight. 2018 Jul 12;3(13). pii: 122092. doi: 10.1172/jci.insight.122092. [Epub ahead of print]

2.

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.

Wrangle JM, Velcheti V, Patel MR, Garrett-Mayer E, Hill EG, Ravenel JG, Miller JS, Farhad M, Anderton K, Lindsey K, Taffaro-Neskey M, Sherman C, Suriano S, Swiderska-Syn M, Sion A, Harris J, Edwards AR, Rytlewski JA, Sanders CM, Yusko EC, Robinson MD, Krieg C, Redmond WL, Egan JO, Rhode PR, Jeng EK, Rock AD, Wong HC, Rubinstein MP.

Lancet Oncol. 2018 May;19(5):694-704. doi: 10.1016/S1470-2045(18)30148-7. Epub 2018 Apr 5.

3.

Alloreactive T Cell Receptor Diversity against Structurally Similar or Dissimilar HLA-DP Antigens Assessed by Deep Sequencing.

Arrieta-Bolaños E, Crivello P, Metzing M, Meurer T, Ahci M, Rytlewski J, Vignali M, Yusko E, van Balen P, Horn PA, Falkenburg JHF, Fleischhauer K.

Front Immunol. 2018 Feb 19;9:280. doi: 10.3389/fimmu.2018.00280. eCollection 2018.

4.

Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis.

Shrimali RK, Ahmad S, Verma V, Zeng P, Ananth S, Gaur P, Gittelman RM, Yusko E, Sanders C, Robins H, Hammond SA, Janik JE, Mkrtichyan M, Gupta S, Khleif SN.

Cancer Immunol Res. 2017 Sep;5(9):755-766. doi: 10.1158/2326-6066.CIR-17-0292.

5.

TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence.

Reuben A, Gittelman R, Gao J, Zhang J, Yusko EC, Wu CJ, Emerson R, Zhang J, Tipton C, Li J, Quek K, Gopalakrishnan V, Chen R, Vence LM, Cascone T, Vignali M, Fujimoto J, Rodriguez-Canales J, Parra ER, Little LD, Gumbs C, Forget MA, Federico L, Haymaker C, Behrens C, Benzeno S, Bernatchez C, Sepesi B, Gibbons DL, Wargo JA, William WN Jr, Swisher S, Heymach JV, Robins H, Lee JJ, Sharma P, Allison JP, Futreal PA, Wistuba II, Zhang J.

Cancer Discov. 2017 Oct;7(10):1088-1097. doi: 10.1158/2159-8290.CD-17-0256. Epub 2017 Jul 21.

6.

Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.

Snyder A, Nathanson T, Funt SA, Ahuja A, Buros Novik J, Hellmann MD, Chang E, Aksoy BA, Al-Ahmadie H, Yusko E, Vignali M, Benzeno S, Boyd M, Moran M, Iyer G, Robins HS, Mardis ER, Merghoub T, Hammerbacher J, Rosenberg JE, Bajorin DF.

PLoS Med. 2017 May 26;14(5):e1002309. doi: 10.1371/journal.pmed.1002309. eCollection 2017 May.

7.

Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade.

Dovedi SJ, Cheadle EJ, Popple AL, Poon E, Morrow M, Stewart R, Yusko EC, Sanders CM, Vignali M, Emerson RO, Robins HS, Wilkinson RW, Honeychurch J, Illidge TM.

Clin Cancer Res. 2017 Sep 15;23(18):5514-5526. doi: 10.1158/1078-0432.CCR-16-1673. Epub 2017 May 22.

8.

Direct measurement of the strength of microtubule attachment to yeast centrosomes.

Fong KK, Sarangapani KK, Yusko EC, Riffle M, Llauró A, Graczyk B, Davis TN, Asbury CL.

Mol Biol Cell. 2017 Jul 7;28(14):1853-1861. doi: 10.1091/mbc.E17-01-0034. Epub 2017 Mar 22.

9.

Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia.

Yin Q, Sivina M, Robins H, Yusko E, Vignali M, O'Brien S, Keating MJ, Ferrajoli A, Estrov Z, Jain N, Wierda WG, Burger JA.

J Immunol. 2017 Feb 15;198(4):1740-1747. doi: 10.4049/jimmunol.1601190. Epub 2017 Jan 11.

10.

Real-time shape approximation and fingerprinting of single proteins using a nanopore.

Yusko EC, Bruhn BR, Eggenberger OM, Houghtaling J, Rollings RC, Walsh NC, Nandivada S, Pindrus M, Hall AR, Sept D, Li J, Kalonia DS, Mayer M.

Nat Nanotechnol. 2017 May;12(4):360-367. doi: 10.1038/nnano.2016.267. Epub 2016 Dec 19.

PMID:
27992411
11.

Tissue distribution and clonal diversity of the T and B cell repertoire in type 1 diabetes.

Seay HR, Yusko E, Rothweiler SJ, Zhang L, Posgai AL, Campbell-Thompson M, Vignali M, Emerson RO, Kaddis JS, Ko D, Nakayama M, Smith MJ, Cambier JC, Pugliese A, Atkinson MA, Robins HS, Brusko TM.

JCI Insight. 2016 Dec 8;1(20):e88242.

12.

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.

Johnson DB, Frampton GM, Rioth MJ, Yusko E, Xu Y, Guo X, Ennis RC, Fabrizio D, Chalmers ZR, Greenbowe J, Ali SM, Balasubramanian S, Sun JX, He Y, Frederick DT, Puzanov I, Balko JM, Cates JM, Ross JS, Sanders C, Robins H, Shyr Y, Miller VA, Stephens PJ, Sullivan RJ, Sosman JA, Lovly CM.

Cancer Immunol Res. 2016 Nov;4(11):959-967. Epub 2016 Sep 26.

13.

Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.

Subudhi SK, Aparicio A, Gao J, Zurita AJ, Araujo JC, Logothetis CJ, Tahir SA, Korivi BR, Slack RS, Vence L, Emerson RO, Yusko E, Vignali M, Robins HS, Sun J, Allison JP, Sharma P.

Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):11919-11924. Epub 2016 Oct 3.

14.

TCR Sequencing Can Identify and Track Glioma-Infiltrating T Cells after DC Vaccination.

Hsu M, Sedighim S, Wang T, Antonios JP, Everson RG, Tucker AM, Du L, Emerson R, Yusko E, Sanders C, Robins HS, Yong WH, Davidson TB, Li G, Liau LM, Prins RM.

Cancer Immunol Res. 2016 May;4(5):412-418. doi: 10.1158/2326-6066.CIR-15-0240. Epub 2016 Mar 11.

15.

Force is a signal that cells cannot ignore.

Yusko EC, Asbury CL.

Mol Biol Cell. 2014 Nov 15;25(23):3717-25. doi: 10.1091/mbc.E13-12-0707. Review.

16.

A model for the interfacial kinetics of phospholipase D activity on long-chain lipids.

Majd S, Yusko EC, Yang J, Sept D, Mayer M.

Biophys J. 2013 Jul 2;105(1):146-53. doi: 10.1016/j.bpj.2013.05.018.

17.

Multivariate analyses of amyloid-beta oligomer populations indicate a connection between pore formation and cytotoxicity.

Prangkio P, Yusko EC, Sept D, Yang J, Mayer M.

PLoS One. 2012;7(10):e47261. doi: 10.1371/journal.pone.0047261. Epub 2012 Oct 15.

18.

Single-particle characterization of Aβ oligomers in solution.

Yusko EC, Prangkio P, Sept D, Rollings RC, Li J, Mayer M.

ACS Nano. 2012 Jul 24;6(7):5909-19. doi: 10.1021/nn300542q. Epub 2012 Jun 21.

19.

Current oscillations generated by precipitate formation in the mixing zone between two solutions inside a nanopore.

Yusko EC, Billeh YN, Mayer M.

J Phys Condens Matter. 2010 Nov 17;22(45):454127. doi: 10.1088/0953-8984/22/45/454127. Epub 2010 Oct 29.

20.

Controlling protein translocation through nanopores with bio-inspired fluid walls.

Yusko EC, Johnson JM, Majd S, Prangkio P, Rollings RC, Li J, Yang J, Mayer M.

Nat Nanotechnol. 2011 Apr;6(4):253-60. doi: 10.1038/nnano.2011.12. Epub 2011 Feb 20.

21.

Applications of biological pores in nanomedicine, sensing, and nanoelectronics.

Majd S, Yusko EC, Billeh YN, Macrae MX, Yang J, Mayer M.

Curr Opin Biotechnol. 2010 Aug;21(4):439-76. doi: 10.1016/j.copbio.2010.05.002. Epub 2010 Jun 18. Review.

22.

Electroosmotic flow can generate ion current rectification in nano- and micropores.

Yusko EC, An R, Mayer M.

ACS Nano. 2010 Jan 26;4(1):477-87. doi: 10.1021/nn9013438.

PMID:
20028119
23.

Gramicidin pores report the activity of membrane-active enzymes.

Majd S, Yusko EC, MacBriar AD, Yang J, Mayer M.

J Am Chem Soc. 2009 Nov 11;131(44):16119-26. doi: 10.1021/ja904072s.

24.

Ultrafast laser fabrication of submicrometer pores in borosilicate glass.

An R, Uram JD, Yusko EC, Ke K, Mayer M, Hunt AJ.

Opt Lett. 2008 May 15;33(10):1153-5.

Supplemental Content

Support Center